CA2887697A1 - Companion diagnostics for tec family kinase inhibitor therapy - Google Patents

Companion diagnostics for tec family kinase inhibitor therapy Download PDF

Info

Publication number
CA2887697A1
CA2887697A1 CA2887697A CA2887697A CA2887697A1 CA 2887697 A1 CA2887697 A1 CA 2887697A1 CA 2887697 A CA2887697 A CA 2887697A CA 2887697 A CA2887697 A CA 2887697A CA 2887697 A1 CA2887697 A1 CA 2887697A1
Authority
CA
Canada
Prior art keywords
probe
kinase
optionally substituted
antibody
tec family
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2887697A
Other languages
English (en)
French (fr)
Inventor
Betty Y. CHANG
Stella CHANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacyclics LLC
Original Assignee
Pharmacyclics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics LLC filed Critical Pharmacyclics LLC
Publication of CA2887697A1 publication Critical patent/CA2887697A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2887697A 2012-10-11 2013-10-11 Companion diagnostics for tec family kinase inhibitor therapy Abandoned CA2887697A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261712675P 2012-10-11 2012-10-11
US61/712,675 2012-10-11
PCT/US2013/064688 WO2014059368A1 (en) 2012-10-11 2013-10-11 Companion diagnostics for tec family kinase inhibitor therapy

Publications (1)

Publication Number Publication Date
CA2887697A1 true CA2887697A1 (en) 2014-04-17

Family

ID=49510539

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2887697A Abandoned CA2887697A1 (en) 2012-10-11 2013-10-11 Companion diagnostics for tec family kinase inhibitor therapy

Country Status (11)

Country Link
US (1) US20150260723A1 (enExample)
EP (1) EP2906556A1 (enExample)
JP (1) JP2015536446A (enExample)
KR (1) KR20150065871A (enExample)
CN (1) CN104755474A (enExample)
AU (1) AU2013328961A1 (enExample)
BR (1) BR112015008042A2 (enExample)
CA (1) CA2887697A1 (enExample)
HK (1) HK1213892A1 (enExample)
MX (1) MX2015004576A (enExample)
WO (1) WO2014059368A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016010961A1 (en) * 2014-07-15 2016-01-21 Abbvie Inc. Enzyme occupancy assay
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
JP2017537327A (ja) 2014-12-11 2017-12-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｂｔｋ阻害剤のアッセイ
WO2016100593A1 (en) * 2014-12-17 2016-06-23 Pharmacyclics Llc Methods and assays for quantification and normalization of kinase and ligand binding
GB201502393D0 (en) * 2015-02-13 2015-04-01 Univ Leicester Senescence
JP6875623B2 (ja) * 2016-02-15 2021-05-26 ノーベルファーマ株式会社 遺伝性疾患に関わるタンパク質の測定方法及び測定キット
EP3484477B1 (en) 2016-07-14 2023-09-13 Mingsight Pharmaceuticals, Inc. Treatment of cancer
CN106405086A (zh) * 2016-09-21 2017-02-15 四川大学华西医院 一种肺癌筛查试剂盒
US20190376971A1 (en) * 2017-01-19 2019-12-12 Acerta Pharma B.V. Compositions and Methods for the Assessment of Drug Target Occupancy for Bruton's Tyrosine Kinase
EP3514541A1 (de) * 2018-01-17 2019-07-24 Siemens Healthcare Diagnostics Products GmbH Verfahren zur quantitativen bestimmung eines therapeutischen tnf-alpha inhibitors
MX2023014435A (es) 2021-06-04 2024-03-08 Janssen Pharmaceutica Nv Inhibidores de la tirosina quinasa de bruton y métodos de su uso.
CN114200145A (zh) * 2022-02-18 2022-03-18 上海益诺思生物技术股份有限公司 酪氨酸激酶浓度的检测方法及试剂盒

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7989465B2 (en) * 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
AU2009262068C1 (en) * 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof

Also Published As

Publication number Publication date
MX2015004576A (es) 2015-07-21
BR112015008042A2 (pt) 2017-07-04
EP2906556A1 (en) 2015-08-19
CN104755474A (zh) 2015-07-01
HK1213892A1 (zh) 2016-07-15
WO2014059368A1 (en) 2014-04-17
AU2013328961A1 (en) 2015-05-07
KR20150065871A (ko) 2015-06-15
US20150260723A1 (en) 2015-09-17
JP2015536446A (ja) 2015-12-21

Similar Documents

Publication Publication Date Title
US20150260723A1 (en) Companion diagnostics for tec family kinase inhibitor therapy
US9810690B2 (en) Method for screening inhibitors of Ras
ES2403546T3 (es) Sonda de actividad de la tirosina-cinasa de Bruton y procedimiento de utilización
TWI499592B (zh) Ｐｉ３激酶抑制劑及其用途
EP2497773B1 (en) Process for preparing a 5H-pyrimido[5,4-d][2]benzazepine
AU2006259153B2 (en) Process for the identification of novel enzyme interacting compounds
CA3130210A1 (en) Cyclin-dependent kinase 2 biomarkers and uses thereof
CA2529238A1 (en) Triazolotriazine compounds and uses thereof
KR20160043534A (ko) 선택적 ｇｒｐ９４ 저해제 및 이의 용도
US20230321083A1 (en) Inhibitors of GPR174 and Uses Thereof
WO2016010961A1 (en) Enzyme occupancy assay
JP2011528560A (ja) 新規キナーゼ阻害剤足場の迅速なスクリーニングおよび同定のための蛍光標識またはスピン標識キナーゼ
Venkatesan et al. Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors
US10125387B2 (en) Compounds, substrates and methods related to histone deacetylases
ES2412380T3 (es) Procedimiento para la identificación de compuestos novedosos que interaccionan con enzimas
RU2619932C1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-а]ПИРИДО[3,4-е]ПИРИМИДИНЫ И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ПРОТЕИНКИНАЗ
JP2020502480A (ja) ２次元ゲル電気泳動における熱安定性変化に基づいた蛍光差を用いた標的タンパク質の識別方法
CN102432612B (zh) 4,7-二氢四唑[1,5-a]嘧啶衍生物及其在制备抗肿瘤药物中的应用
US20230405135A1 (en) Therapeutic conjugates
Sharlow et al. Development and implementation of a miniaturized high-throughput time-resolved fluorescence energy transfer assay to identify small molecule inhibitors of polo-like kinase 1
WO2016100593A1 (en) Methods and assays for quantification and normalization of kinase and ligand binding
US20240351996A1 (en) Cdk19-selective inhibitors, and methods of use thereof
Mazzucato Design and Synthesis of Novel Kinase Inhibitors for the Treatment of Chronic Respiratory Diseases
Misehe Design, synthesis and evaluation of novel inhibitors of class II PI4Ks and RIPK2/3 kinases
King Utilizing Proteolysis-Targeting Chimeras to Target the Transcriptional Cyclin-Dependent Kinases 9 and 12

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20181011